Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Sacubitril/valsartan

Details

Request for Resubmission: Eligible (Decision Date: January 6, 2020)

Last Updated : August 4, 2015

Jakavi for Polycythemia Vera - Details

Details

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : March 18, 2016

Blinatumomab (Blincyto) for Ph- ALL

Details

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : April 18, 2016

Opdivo for Metastatic Melanoma - Details

Details

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : April 18, 2016

Fluticasone Furoate and Vilanterol (as trifenatate)

Details

Request for Resubmission: Eligible (Decision Date: January 15, 2018)

Last Updated : January 15, 2018